Study Shows Promise for Nonhormonal Reversible Male Contraceptive Targeting STK33 in Mice

May 24, 2024, 10:14 AM

A new study has highlighted the potential of STK33, a protein essential for male fertility in humans and mice, as a target for nonhormonal and reversible male contraceptives. The study, sponsored by Promega and published in Science Magazine, demonstrated the effectiveness of CDD-2807, a tool compound that achieves reversible inhibition of spermatogenesis in mice. An injection that temporarily affects sperm movement has shown promise as a potential male contraceptive. The targeted inhibition of serine/threonine kinase 33 is central to this contraceptive method.